EGFR and non-small cell lung carcinoma: Finally, 752 patients remained, who had been diagnosed with EGFR-mutant nonsquamous NSCLC with actionable EGFR mutation variants, and had started treatment with erlotinib or gefitinib prior to October 2020 for inclusion in this study.